Abbott settles antitrust allegations over TriCor

Abbott Laboratories stated in a regulatory filing that it intends to pay $184 million to settle class-action claims from pharmacies, wholesalers and generic-drug firms alleging that the company breached antitrust laws by working to block the launch of copies of its cholesterol drug TriCor. Abbott contends that it acted in accordance with the law and agreed to the settlement "to avoid the uncertainty of a trial outcome," a company spokeswoman said.

View Full Article in:

Wall Street Journal, The · Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ